{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:14:06Z","timestamp":1684469646427},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1038\/ncpneph0114","type":"journal-article","created":{"date-parts":[[2006,5,16]],"date-time":"2006-05-16T17:16:14Z","timestamp":1147799774000},"page":"169-172","source":"Crossref","is-referenced-by-count":3,"title":["Alcoholic cirrhosis-associated hepatorenal syndrome treated with vasoactive agents"],"prefix":"10.1038","volume":"2","author":[{"given":"Eric","family":"Esrailian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce A","family":"Runyon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFncpneph0114_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/hep.510230122","volume":"23","author":"V Arroyo","year":"1996","unstructured":"Arroyo V et al. (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 23: 164\u2013176","journal-title":"Hepatology"},{"key":"BFncpneph0114_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","volume":"105","author":"A Gin\u00e9s","year":"1993","unstructured":"Gin\u00e9s A et al. (1993) Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology 105: 229\u2013236","journal-title":"Gastroenterology"},{"key":"BFncpneph0114_CR3","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1053\/gast.2002.33575","volume":"122","author":"V Arroyo","year":"2002","unstructured":"Arroyo V et al. (2002) Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 122: 1658\u20131676","journal-title":"Gastroenterology"},{"key":"BFncpneph0114_CR4","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1053\/jhep.2001.29200","volume":"34","author":"F Wong","year":"2001","unstructured":"Wong F and Blendis L (2001) New challenge of hepatorenal syndrome: prevention and treatment. Hepatology 34: 1242\u20131251","journal-title":"Hepatology"},{"key":"BFncpneph0114_CR5","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/hep.20066","volume":"39","author":"BA Runyon","year":"2004","unstructured":"Runyon BA et al. (2004) Management of adult patients with ascites due to cirrhosis. Hepatology 39: 841\u2013856","journal-title":"Hepatology"},{"issue":"Suppl","key":"BFncpneph0114_CR6","doi-asserted-by":"publisher","first-page":"A718","DOI":"10.1016\/S0016-5085(03)83625-9","volume":"124","author":"E Esrailian","year":"2003","unstructured":"Esrailian E et al. (2003) Octreotide\/midodrine therapy significantly improves survival in type 1 hepatorenal syndrome: analysis of 53 treated patients and 21 controls. [abstract #525] Gastroenterology 124 (Suppl): A718","journal-title":"Gastroenterology"},{"key":"BFncpneph0114_CR7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/hep.1840060216","volume":"6","author":"FJ Dudley","year":"1986","unstructured":"Dudley FJ et al. (1986) Hepatorenal syndrome without avid sodium retention. Hepatology 6: 248\u2013251","journal-title":"Hepatology"},{"key":"BFncpneph0114_CR8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/00007890-199502150-00010","volume":"59","author":"TA Gonwa","year":"1995","unstructured":"Gonwa TA et al. (1995) Impact of pretransplant renal function on survival after liver transplantation. Transplantation 59: 361\u2013365.","journal-title":"Transplantation"},{"key":"BFncpneph0114_CR9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/00007890-199102000-00030","volume":"91","author":"TA Gonwa","year":"1991","unstructured":"Gonwa TA et al. (1991) Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome\u2014experience in 300 patients. Transplantation 91: 428\u2013430","journal-title":"Transplantation"},{"key":"BFncpneph0114_CR10","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/hep.510300430","volume":"30","author":"V Gulberg","year":"1999","unstructured":"Gulberg V et al. (1999) Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 30: 870\u2013875","journal-title":"Hepatology"},{"key":"BFncpneph0114_CR11","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1111\/j.1572-0241.2000.03214.x","volume":"95","author":"C Duhamel","year":"2000","unstructured":"Duhamel C et al. (2000) Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors? Am J Gastroenterol 95: 2984\u20132985","journal-title":"Am J Gastroenterol"},{"key":"BFncpneph0114_CR12","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1053\/gast.2002.32364","volume":"122","author":"R Moreau","year":"2002","unstructured":"Moreau R et al. (2002) Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122: 923\u2013930","journal-title":"Gastroenterology"},{"key":"BFncpneph0114_CR13","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/hep.510290629","volume":"29","author":"P Angeli","year":"1999","unstructured":"Angeli P et al. (1999) Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 29: 1690\u20131697","journal-title":"Hepatology"},{"key":"BFncpneph0114_CR14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/hep.510280219","volume":"28","author":"M Guevara","year":"1998","unstructured":"Guevara M et al. (1998) Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 28: 416\u2013422","journal-title":"Hepatology"},{"key":"BFncpneph0114_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/hep.20262","volume":"40","author":"F Wong","year":"2004","unstructured":"Wong F et al. (2004) Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 40: 55\u201364","journal-title":"Hepatology"}],"container-title":["Nature Clinical Practice Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0114","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/ncpneph0114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/ncpneph0114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:11:46Z","timestamp":1684440706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpneph0114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["BFncpneph0114"],"URL":"https:\/\/doi.org\/10.1038\/ncpneph0114","relation":{},"ISSN":["1745-8323","1745-8331"],"issn-type":[{"value":"1745-8323","type":"print"},{"value":"1745-8331","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}